Premium
Comparison of the pharmacokinetics of tilmicosin in plasma and lung tissue in healthy chickens and chickens experimentally infected with Mycoplasma gallisepticum
Author(s) -
Zhang Nan,
Liu Zhenxian,
Wei Yanzhe,
Zhang Chuanzhen,
Mao Chunxiao,
Cai Qinren,
Shen Xiangguang,
Ding Huanzhong
Publication year - 2020
Publication title -
journal of veterinary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.527
H-Index - 60
eISSN - 1365-2885
pISSN - 0140-7783
DOI - 10.1111/jvp.12847
Subject(s) - tilmicosin , mycoplasma gallisepticum , pharmacokinetics , lung , biology , veterinary medicine , medicine , mycoplasma , pharmacology , microbiology and biotechnology , antibiotics
The objectives of this study were to compare the plasma and lung tissue pharmacokinetics of tilmicosin in healthy and Mycoplasma gallisepticum ‐infected chickens . Tilmicosin was orally administered at 4, 7.5 and 10 mg/kg body weight (b.w) for the infected and 7.5 mg/kg b.w for the uninfected control group. We found no significant differences in plasma tilmicosin pharmacokinetics between diseased and healthy control chickens. In contrast, the lung tissues in M. gallisepticum ‐infected chickens displayed a t 1/2 (elimination half‐life) 1.76 times longer than for healthy chickens. The C max (the maximum concentration of drug in samples) of tilmicosin in M. gallisepticum ‐infected chickens was lower than for controls at 7.5 mg/kg b.w ( p < .05), and the AUC inf (the area under the concentration–time curve from time 0 extrapolated to infinity) in infected chickens was higher than for the healthy chickens ( p < .05). The mean residence time of tilmicosin in infected chickens was also higher than the healthy chickens. These results indicated that the lungs of healthy chickens had greater absorption of tilmicosin than the infected chickens, and the rate of elimination of tilmicosin from infected lungs was slower.